Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.018 AUD | 0.00% |
|
0.00% | -48.57% |
May. 22 | Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4% | MT |
May. 20 | Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-48.57% | 10.67M | |
+20.12% | 127B | |
+25.25% | 117B | |
+25.56% | 27.77B | |
-19.51% | 20.44B | |
-14.36% | 16.62B | |
-15.63% | 15.92B | |
-46.67% | 14.94B | |
+11.89% | 14.74B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- CHM Stock
- News Chimeric Therapeutics Limited
- Chimeric Therapeutics Opens Phase 1B Leukemia Trial